Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE 3: LY2605541 versus insulin glargine in adults with type 1 diabetes
NL-OMON37811Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin peglispro in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 52 weeks. Started Dec 2012; status: active, not recruiting.
02
Drugs
insulin peglispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON37811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37811.